Share on StockTwits

Prosensa Holding NV (NYSE:RNA) announced its earnings results on Tuesday. The company reported ($0.29) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.36) by $0.07, Analyst Ratings News reports.

Shares of Prosensa Holding NV (NYSE:RNA) opened at 10.34 on Tuesday. Prosensa Holding NV has a one year low of $3.43 and a one year high of $30.11. The stock’s 50-day moving average is $10.48 and its 200-day moving average is $7.91. The company’s market cap is $372.0 million.

A number of research firms have recently commented on RNA. Analysts at Oppenheimer initiated coverage on shares of Prosensa Holding NV in a research note on Thursday, July 31st. They set an “outperform” rating and a $25.00 price target on the stock. On a related note, analysts at Roth Capital upgraded shares of Prosensa Holding NV from a “neutral” rating to a “buy” rating in a research note on Monday, July 28th. They now have a $17.00 price target on the stock, up previously from $12.00. Finally, analysts at Roth Capital initiated coverage on shares of Prosensa Holding NV in a research note on Wednesday, June 18th. They set a “neutral” rating and a $12.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $13.92.

Prosensa Holding N.V., formerly Prosensa Holding B.V., is a biotechnology company engaged in the discovery and development of ribonucleic acid-modulating (NYSE:RNA)-modulating, therapeutics for the treatment of genetic disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.